Spinogenix

Spinogenix, Inc. is a biotechnology company developing investigational treatments focused on restoring brain synapses, the connections that support communication between nerve cells. Its approach uses small molecules designed to help rebuild or restore these connections, addressing synaptic loss associated with neurological and mental health conditions. The company’s research spans neurodegenerative, neuropsychiatric and neurodevelopmental disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, schizophrenia and Fragile X syndrome.

Spinogenix’s portfolio includes oral investigational therapies such as tazbentetol and SPG601, which are being studied for potential therapeutic benefits. The company shares information about its science, clinical pipeline, research publications and trial-related updates, and provides resources for patients and families, including an expanded access policy. Its work is intended to advance new treatment approaches and improve the lives of people affected by these conditions. Spinogenix is headquartered in Los Angeles and communicates with the public through press releases, educational materials and updates on its research and development programs. Its therapies remain investigational and are not described as approved treatments.